However, MAP7 was the only gene that was identified by overlapping our results with previous reports included in a 24-gene AML prognostic signature8, indicating that MAP7high may be an adverse biomarker in both CN-AML and AML. The gene discussed is MAP7; the disease is acute myeloid leukemia.